



**OUTLINE OF ACTIVE TRIALS WITH TENOFOVIR ALAFENAMIDE
JULY 2021**

Study Title: A Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)

Sponsor: Gilead Sciences, Inc.
333 Lakeside Drive
Foster City
CA 94404
USA

EudraCT Number: 2021-000672-11

Indication: Chronic hepatitis B virus (HBV) infection

Protocol ID: GS-US-465-4439

The following clinical trials with Tenofovir alafenamide are approved and ongoing in the European Union:

Study number (EudraCT number)	Study title	Member States
GS-US-320-0108 (2013-000626-63)	A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Negative, Chronic Hepatitis B	FR, IT, PL, RO, ES
GS-US-320-0110 (2013-000636-10)	A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Positive, Chronic Hepatitis B	BG, FR, IT, PL, RO, ES

Study number (EudraCT number)	Study title	Member States
GS-US-320-1092 (2016-000785-37)	A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Children and Adolescent Subjects with Chronic Hepatitis B Virus Infection	RO